Loading...
Loading...
ALXO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 41.3M |
| Operating I/L | -41.5M |
| Other Income/Expense | 2.1M |
| Interest Income | 2.6M |
| Pretax | -39.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -39.4M |
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company specializing in the development of cancer therapies. Its lead product candidate, ALX148, is a CD47 blocking therapeutic undergoing Phase 1b/2 clinical trials for the treatment of myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and various solid tumor indications. The company also offers pre-clinical products such as ALTA-002, a SIRPa TRAAC designed to engage the immune response to cancer. ALX Oncology has collaboration agreements with Merck, Zymeworks, and Tallac Therapeutics for the development and commercialization of cancer immunotherapeutics, driving its revenue through partnerships and product development.
